Zhang Lei, Ye Biwei, Chen Zhuo, Chen Zhe-Sheng
State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, China.
University of Chinese Academy of Sciences, Beijing 100049, China.
Acta Pharm Sin B. 2023 Mar;13(3):982-997. doi: 10.1016/j.apsb.2022.10.002. Epub 2022 Oct 7.
Chemotherapy is one of the important methods to treat cancer, and the emergence of multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy. Almost all anti-tumor drugs develop drug resistance over a period of time of application in cancer patients, reducing their effects on killing cancer cells. Chemoresistance can lead to a rapid recurrence of cancers and ultimately patient death. MDR may be induced by multiple mechanisms, which are associated with a complex process of multiple genes, factors, pathways, and multiple steps, and today the MDR-associated mechanisms are largely unknown. In this paper, from the aspects of protein-protein interactions, alternative splicing (AS) in pre-mRNA, non-coding RNA (ncRNA) mediation, genome mutations, variance in cell functions, and influence from the tumor microenvironment, we summarize the molecular mechanisms associated with MDR in cancers. In the end, prospects for the exploration of antitumor drugs that can reverse MDR are briefly discussed from the angle of drug systems with improved targeting properties, biocompatibility, availability, and other advantages.
化疗是治疗癌症的重要方法之一,而多药耐药性(MDR)的出现是癌症化疗失败的一个主要原因。几乎所有抗肿瘤药物在癌症患者应用一段时间后都会产生耐药性,降低其对癌细胞的杀伤作用。化疗耐药可导致癌症迅速复发并最终导致患者死亡。MDR可能由多种机制诱导,这些机制与多个基因、因子、途径和多个步骤的复杂过程相关,而目前与MDR相关的机制在很大程度上尚不清楚。本文从蛋白质-蛋白质相互作用、前体mRNA中的可变剪接(AS)、非编码RNA(ncRNA)介导、基因组突变、细胞功能变化以及肿瘤微环境的影响等方面,总结了癌症中与MDR相关的分子机制。最后,从具有改善的靶向性、生物相容性、可及性等优点的药物系统角度,简要讨论了探索能够逆转MDR的抗肿瘤药物的前景。
Drug Resist Updat. 2021-3
Drug Resist Updat. 2020-5
Cancer Chemother Pharmacol. 1997
Expert Opin Drug Metab Toxicol. 2021-3
Biochim Biophys Acta. 2016-12
Biomedicines. 2025-5-20
Future Med Chem. 2025-5
Future Med Chem. 2025-4
Cancer Drug Resist. 2019-9-19
Front Cell Dev Biol. 2022-4-20
J Control Release. 2022-6
Front Pharmacol. 2022-4-1